title: Beta-adrenergic stimulation reverses postischemic myocardial dysfunction without producing subsequent functional deterioration.
abstract: The prolonged myocardial dysfunction observed after reversible ischemia (stunned myocardium) has been postulated to result from an inability of the myocytes to replenish ATP stores. Accordingly, one would expect inotropic stimulation to result in minimal increase in contractile function, or possibly even further deterioration. To test this hypothesis, studies were performed in open-chest dogs undergoing a 15-minute occlusion of the left anterior descending coronary artery (LAD) followed by 4 hours of reperfusion. Systolic wall thickening, an index of regional myocardial function, was measured in the LAD-dependent territory with ultrasonic crystals. Thickening fraction was 20.8 +/- 3.0% (mean +/- standard error of the mean) under baseline conditions, decreased to -18.6 +/- 1.6% during LAD occlusion, and was still severely depressed after 3 hours of reperfusion (2.6 +/- 3.4%). Thickening fraction remained stable between 3 and 4 hours of reperfusion in 5 untreated control dogs. In 9 treated dogs, isoproterenol (0.1 microgram/kg/min intravenously for 30 minutes starting 3 hours after reperfusion) increased thickening fraction to values (24.8 +/- 4.5%) that were similar to those at baseline. Thirty minutes after discontinuation of isoproterenol administration, thickening fraction had returned to pre-isoproterenol levels. Thus, reperfused, severely depressed myocardium responds dramatically to beta-adrenergic stimulation without subsequent adverse effects on function in the short-term. These findings imply that the stunned myocardium can generate ATP, and therefore do not support the view that an inability to replenish ATP stores is the cause of postischemic dysfunction. More important, this study suggests that postischemic dysfunction in humans may be effectively reversed with inotropic therapy without short-term deleterious sequelae.
authors.forename: R
authors.initials: R
authors.lastname: Bolli
authors.forename: W X
authors.initials: WX
authors.lastname: Zhu
authors.forename: M L
authors.initials: ML
authors.lastname: Myers
authors.forename: C J
authors.initials: CJ
authors.lastname: Hartley
authors.forename: R
authors.initials: R
authors.lastname: Roberts
mesh_terms: D000255:Adenosine Triphosphate / Q000096:biosynthesis; D000318:Adrenergic beta-Agonists / Q000494:pharmacology*; D000818:Animals; D003327:Coronary Disease / Q000503:physiopathology*; D004285:Dogs; D005260:Female; D006321:Heart / Q000187:drug effects / Q000503:physiopathology*; D006439:Hemodynamics / Q000187:drug effects; D007545:Isoproterenol / Q000494:pharmacology; D008297:Male; D009200:Myocardial Contraction / Q000187:drug effects
chemical_list: D000318:Adrenergic beta-Agonists; D000255:Adenosine Triphosphate; D007545:Isoproterenol